Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04938232 |
Recruitment Status :
Active, not recruiting
First Posted : June 24, 2021
Last Update Posted : March 20, 2024
|
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Reid Merryman, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Actual Primary Completion Date : | March 1, 2024 |
Estimated Study Completion Date : | August 1, 2026 |